BioTrove Inc., a Woburn, Mass.-based maker of instruments and consumables for genomic analysis, high-throughput screening and molecular diagnostics, has withdrawn registration for a $75 million IPO, citing unfavorable market conditions. It had planned to trade on the Nasdaq, with Piper Jaffray and Lazard Capital Markets serving as co-lead underwriters.
BioTrove has raised over $43 million in VC funding since 2002, from firms like Catalyst Health & Technology Partners (35.1% pre-IPO stake), CB Health Ventures (17.1%), Vox Equity Partners (14.3%), Biofrontier Partners (6.1%), Fletcher Spaght Associates (6.2%) and Pfizer. www.biotrove.com
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.